Oncology Xagena
Breast cancer patients with HER2-positive tumors who don't respond to Herceptin ( Trastuzumab ) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...
New data from an international, multicenter Phase III clinical trial has found that the experimental targeted therapy everolimus ( RAD001 ) significantly delays cancer progression in patients with m ...
Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...
Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. Resear ...
Results from CheckMate -025, a phase 3 study comparing Nivolumab ( Opdivo ) to Everolimus ( Afinitor ) in advanced renal cell carcinoma ( RCC ) after prior anti-angiogenic treatment, showed a signific ...
Neuroendocrine tumors ( NETs ) are a heterogeneous class of neoplasms with increasing incidence worldwide. Tumor behavior and patient survival largely depend upon a number of different factors such ...
A phase II trial of Everolimus plus Octreotide LAR as first-line treatment for patients with previously untreated, well-differentiated gastroenteropancreatic NETs and NETs of lung origin, both functio ...
Final results from the randomised phase III METEOR study have confirmed the superiority of Cabozantinib over Everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma ( mRCC ) ...
While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...
Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...
